File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The economics of Alzheimer disease

TitleThe economics of Alzheimer disease
Authors
Issue Date2003
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/DEM
Citation
Dementia And Geriatric Cognitive Disorders, 2003, v. 15 n. 1, p. 34-43 How to Cite?
AbstractEconomic assessments of health and healthcare have become an integral part of policy decisions in the last decade. Increasingly, this trend is extending to medical decision-making in day-to-day patient-provider interactions. Alzheimer disease (AD) offers a potent example of the clinical and economic issues at stake with its diagnostic techniques, pharmacotherapies, and public health and policy implications. This review introduces basic economic concepts in examining the impact of AD and related care. It presents a summary of the latest economics research on cost estimates of AD and on economic evaluations of diagnostic and management interventions in terms of cost-of-illness and cost-effectiveness studies respectively. Empirical and conceptual issues about the interpretation of costs and the uses of evaluative methods are also discussed. We found that the economic costs attributable to AD care is highly variable mostly due to non-standardised methodologies and geographical variations in care patterns. There is, however, little doubt that the impact is substantial and is expected to worsen with the demographic, epidemiologic, technologic and economic transitions worldwide. There are comparatively fewer studies on the cost-effectiveness of interventions in AD. Most of the published work revolves around pharmacotherapeutics while relatively little has been done on diagnostics, patient care programmes and programmes for caregivers. We conclude that there are significant opportunities to strengthen research on standardised cost-of-illness analyses and new cost-effectiveness studies on a broader range of AD interventions. Copyright © 2003 S. Karger AG, Basel.
Persistent Identifierhttp://hdl.handle.net/10722/86837
ISSN
2015 Impact Factor: 3.408
2015 SCImago Journal Rankings: 1.194
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, GMen_HK
dc.contributor.authorYeung, RYTen_HK
dc.contributor.authorChi, Ien_HK
dc.contributor.authorChu, LWen_HK
dc.date.accessioned2010-09-06T09:21:56Z-
dc.date.available2010-09-06T09:21:56Z-
dc.date.issued2003en_HK
dc.identifier.citationDementia And Geriatric Cognitive Disorders, 2003, v. 15 n. 1, p. 34-43en_HK
dc.identifier.issn1420-8008en_HK
dc.identifier.urihttp://hdl.handle.net/10722/86837-
dc.description.abstractEconomic assessments of health and healthcare have become an integral part of policy decisions in the last decade. Increasingly, this trend is extending to medical decision-making in day-to-day patient-provider interactions. Alzheimer disease (AD) offers a potent example of the clinical and economic issues at stake with its diagnostic techniques, pharmacotherapies, and public health and policy implications. This review introduces basic economic concepts in examining the impact of AD and related care. It presents a summary of the latest economics research on cost estimates of AD and on economic evaluations of diagnostic and management interventions in terms of cost-of-illness and cost-effectiveness studies respectively. Empirical and conceptual issues about the interpretation of costs and the uses of evaluative methods are also discussed. We found that the economic costs attributable to AD care is highly variable mostly due to non-standardised methodologies and geographical variations in care patterns. There is, however, little doubt that the impact is substantial and is expected to worsen with the demographic, epidemiologic, technologic and economic transitions worldwide. There are comparatively fewer studies on the cost-effectiveness of interventions in AD. Most of the published work revolves around pharmacotherapeutics while relatively little has been done on diagnostics, patient care programmes and programmes for caregivers. We conclude that there are significant opportunities to strengthen research on standardised cost-of-illness analyses and new cost-effectiveness studies on a broader range of AD interventions. Copyright © 2003 S. Karger AG, Basel.en_HK
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/DEMen_HK
dc.relation.ispartofDementia and Geriatric Cognitive Disordersen_HK
dc.rightsDementia and Geriatric Cognitive Disorders. Copyright © S Karger AG.en_HK
dc.subject.meshAlzheimer Disease - economics - therapyen_HK
dc.subject.meshCaregivers - economicsen_HK
dc.subject.meshCost of Illnessen_HK
dc.subject.meshCost-Benefit Analysisen_HK
dc.subject.meshDecision Makingen_HK
dc.subject.meshHumansen_HK
dc.titleThe economics of Alzheimer diseaseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1420-8008&volume=15&spage=34&epage=43&date=2003&atitle=The+economics+of+Alzheimer+diseaseen_HK
dc.identifier.emailLeung, GM:gmleung@hku.hken_HK
dc.identifier.authorityLeung, GM=rp00460en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000066675en_HK
dc.identifier.pmid12457077-
dc.identifier.scopuseid_2-s2.0-0037211638en_HK
dc.identifier.hkuros75566en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037211638&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume15en_HK
dc.identifier.issue1en_HK
dc.identifier.spage34en_HK
dc.identifier.epage43en_HK
dc.identifier.isiWOS:000179900600006-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridLeung, GM=7007159841en_HK
dc.identifier.scopusauthoridYeung, RYT=7102833306en_HK
dc.identifier.scopusauthoridChi, I=7005697907en_HK
dc.identifier.scopusauthoridChu, LW=7202236665en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats